SeeThruEquity Initiates Research Coverage on Aethlon Medical, Inc. with Target Price of $0.34
New York, NY / ACCESSWIRE / September 22, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Aethlon Medical, Inc. (AEMD), a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
"We see the core of AEMD’s developments in the Aethlon ADAPT(TM) (Adaptive Dialysis-Like Affinity Platform Technology) system, a medical device platform that forms the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT(TM) product is Hemopurifier(R), a first-in-class device that addresses a broad spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients," commented Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a target price of $0.34."
Additional investment highlights are as follows:
Unique therapeutic model
Aethlon Medical is developing revolutionary medical devices under the Aethlon ADAPT(TM) (Adaptive Dialysis-like Affinity Platform Technology) system that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. In recent times, development of new drugs has become costly, slow, and unsustainable. An estimated 4,000 biopharma companies with 4 million employees spend billions of dollars each year on research but only a handful of drugs get FDA approval. Only 1 drug for every 10,000 candidates gets FDA approval after 15 years of rigorous research and clinical trials, resulting in R&D costs of $4-12 billion per drug approval. The Aethlon Model improves approved and candidate drugs by rapid elimination of drug target, eliminating targets beyond drugs, preserving immune cells and adding benefit without drug toxicity. We believe AEMD’s business model is unique in that its therapeutic systems could be used in conjunction with drugs or standalone, dramatically improving patient outcomes and saving lives.
Initiating U.S. studies for Hemopurifier(R) Therapy
In May 2014, AEMD disclosed that its lead ADAPT(TM) product, Hemopurifier(R), received the U.S. FDA approval as an Investigational Device Exemption (IDE) device, which allows the company to initiate HCV human feasibility studies of Hemopurifier(R) therapy in the U.S. The first U.S. clinical study will be conducted at the DaVita MedCenter Dialysis in Houston, Texas. Under the feasibility study protocol, Aethlon is to treat ten ESRD patients infected with Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease indications.
Large disease markets
Based on issued patents and/or clinical validations relating to Exosomes, AEMD can target the extracorporeal cancer therapy (Breast, Ovarian, Melanoma, Lymphoma), Infectious Disease (HIV and HCV Drug Resistance), and Emerging Pandemic & Bioterror Threat markets, among others. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation. AEMD’s Hemopurifier is an antiviral broad-spectrum candidate that offers a solution for antiviral drug resistance in HIV/AIDS Hepatitis C Virus (HCV).
The report is available here: AEMD Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.
About Aethlon Medical, Inc.
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier(R), a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
(646) 495-0939
SOURCE: SeeThruEquity
